Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

September 30, 2015

Conditions
Hookworm InfectionHookworm Disease
Interventions
BIOLOGICAL

Na-APR-1 (M74)/Alhydrogel®

The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.

BIOLOGICAL

Gluco-Pyranosylphospho-Lipid A Aqueous Formulation

GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.

Trial Locations (1)

20036

George Washington University Medical Faculty Associates, Washington D.C.

All Listed Sponsors
collaborator

George Washington University

OTHER

lead

Baylor College of Medicine

OTHER

NCT01717950 - Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter